Cover Image
市場調查報告書

急性腎功能衰竭(ARF,急性腎障礙):開發平台分析

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 213122
出版日期 內容資訊 英文 134 Pages
訂單完成後即時交付
價格
Back to Top
急性腎功能衰竭(ARF,急性腎障礙):開發平台分析 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2017
出版日期: 2017年02月28日 內容資訊: 英文 134 Pages
簡介

所謂急性腎功能衰竭(ARF),是腎臟過濾血液廢物的功能突然降低這樣的疾病。主要的症狀有睡意和呼吸急促、倦怠感、胸部疼痛,生命垂危時有痙攣和昏睡狀態等。主要的易罹病素質為,老齡化和糖尿病、高血壓、心臟衰竭、腎臟疾病等。主要的治療藥有抗生素和利尿劑等。

本報告提供全球各國治療急性腎功能衰竭(急性腎障礙)用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

急性腎功能衰竭(ARF)概要

治療藥的開發

  • 急性腎功能衰竭開發中產品:概要
  • 急性腎功能衰竭開發中產品:比較分析

各企業正在開發的急性腎功能衰竭治療藥

大學/研究機關研究中的急性腎功能衰竭治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

急性腎功能衰竭治療藥:開發中的產品一覽(各企業)

急性腎功能衰竭治療藥:研究中的產品一覽(大學/研究機關別)

急性腎功能衰竭開發治療藥的企業

  • A1M Pharma AB
  • Adrenomed AG
  • Am-Pharma B.V.
  • Angion Biomedica Corp.
  • Atox Bio Inc.
  • Cellmid Limited
  • Complexa, Inc.
  • DiaMedica Inc.
  • Digna Biotech, S.L.
  • DURECT Corporation
  • F. Hoffmann-La Roche Ltd.
  • G1 Therapeutics, Inc.
  • Ischemix, Inc.
  • kuringurufama
  • NephroGenex, Inc.
  • NeuroVive Pharmaceutical AB
  • Noorik Biopharmaceuticals AG
  • Noxxon Pharma AG
  • Nyken B.V.
  • Orion Oyj
  • ProMetic Life Sciences Inc.
  • Quark Pharmaceuticals, Inc.
  • SBI Pharmaceuticals Co., Ltd.
  • Spherium Biomed S.L.
  • STATegics, Inc.
  • Thrasos Therapeutics Inc.
  • Torrent Pharmaceuticals Limited

急性腎功能衰竭:治療藥的評估

  • 單劑治療藥的情況
  • 並用治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • (aminolevulinic acid hydrochloride + sodium ferrous citrate)
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • A1M-001
  • AB-103
  • adrecizumab
  • BB-3
  • CAB-101
  • Cardiotrophin-1
  • Cell Therapy to Activate Wnt7b for Kidney Injury
  • CMX-2043
  • CXA-10
  • cyclosporine
  • DM-199
  • DUR-928
  • HYPER-IL-6
  • KP-100IT
  • levosimendan
  • MG-53
  • MTP-131
  • N-003
  • NOXD-21
  • NYK-1341
  • PBI-4419
  • Pyridoxamine Dihydrochloride
  • QPI-1002
  • R-190
  • Recombinant Human Alkaline Phosphatase Replacement for Ulcerative Colitis, Acute Renal Failure, Sepsis and Hypophosphatasia
  • Recombinant Protein for Sepsis, Inflammatory Bowel Disease, Acute Kidney Injury, Acute Radiation Syndrome and Ischemic Organ Injury
  • RLS-003
  • RO-6839328
  • Small Molecule to Inhibit CDK4 and CDK6 for Acute Kidney Injury and Breast Cancer
  • Small Molecule to Inhibit HDAC for Acute Kidney Injury
  • SP-15016
  • STSE-15
  • THR-184
  • TRC-160334

急性腎功能衰竭治療藥:開發中產品的最新趨勢

急性腎功能衰竭治療藥:開發暫停的產品

急性腎功能衰竭治療藥:開發中止的產品

急性腎功能衰竭相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8976IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2017, provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline landscape.

Acute kidney failure occurs when kidneys suddenly become unable to filter waste products from blood. Symptoms include drowsiness, shortness of breath, fatigue, seizures or coma in severe cases and chest pain. The predisposing factors include age, diabetes, high blood pressure, heart failure and kidney diseases. Treatment includes antibiotics and diuretics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 5, 7, 1, 19, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Overview
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Companies Involved in Therapeutics Development
  • A1M Pharma AB
  • Alloksys Life Sciences BV
  • Am-Pharma BV
  • Angion Biomedica Corp
  • Atox Bio Ltd
  • Cellmid Ltd
  • Complexa Inc
  • DiaMedica Therapeutics Inc
  • DURECT Corp
  • Evotec AG
  • Exponential Biotherapies Inc
  • F. Hoffmann-La Roche Ltd
  • G1 Therapeutics Inc
  • Kringle Pharma Inc
  • Mitotech SA
  • NephroGenex Inc
  • NeuroVive Pharmaceutical AB
  • Nyken BV
  • ProMetic Life Sciences Inc
  • Quark Pharmaceuticals Inc
  • Regulus Therapeutics Inc
  • SBI Pharmaceuticals Co Ltd
  • Spherium Biomed SL
  • STATegics Inc
  • Stealth BioTherapeutics Inc
  • Thrasos Therapeutics Inc
  • Torrent Pharmaceuticals Ltd
  • Xigen SA
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Drug Profiles
  • (aminolevulinic acid hydrochloride + sodium ferrous citrate) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • A1M-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AB-103 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Antisense RNAi Oligonucleotides for Acute Kidney Injury and Chronic Kidney Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BB-3 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • brimapitide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CAB-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CXA-10 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • DM-199 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Drug for Kidney Diseases - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • DUR-928 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • EA-230 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • elamipretide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • KP-100IT - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MG-53 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NOXD-21 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NVP-019 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NYK-1341 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PBI-4419 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Plastomitin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Pyridoxamine Dihydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • QPI-1002 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • R-190 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Recombinant Human Alkaline Phosphatase - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Recombinant Human Alkaline Phosphatase Replacement for Acute Renal Failure, Hypophosphatasia, Sepsis and Ulcerative Colitis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury, and Sepsis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RLS-003 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RMC-035 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RO-6839328 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit CDK4 and CDK6 for Acute Kidney Injury and Breast Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit HDAC for Acute Kidney Injury - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SP-15016 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • STSE-15 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • THR-184 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TRC-160334 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Vanadis-03 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Discontinued Products
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Product Development Milestones
  • Featured News & Press Releases
  • Feb 10, 2017: A1M Pharma has successfully conducted large scale manufacturing of the active substance in ROSGard and initiates GLP toxicology studies
  • Jan 31, 2017: Angion Biomedica Phase 2 "GUARD" Clinical Trial of BB3 in Acute Kidney Injury (AKI) Underway; Complements Ongoing Phase 3 Study in Renal Transplant Recipients with Delayed Graft Function
  • Jan 30, 2017: DURECT Announces Update on DUR-928 Development Program
  • Dec 20, 2016: Silence Therapeutics Announces Quark Arbitration Resolution
  • Dec 09, 2016: ROSGard shows renal protective effect during radiation therapy
  • Nov 07, 2016: Stealth BioTherapeutics Announces Acceptance of Late-Breaking Clinical Trial Poster at American Society of Nephrology Kidney Week 2016
  • Sep 19, 2016: Quark Pharmaceuticals to provide an update on kidney transplant drug QPI-1002
  • Sep 13, 2016: A1M Pharma selects kidney protection in connection with cancer treatment as their first indication within acute kidney injury
  • May 10, 2016: AM-Pharma publishes safety and pharmacokinetic data from Phase I recAP trial
  • Apr 26, 2016: AM-Pharma receives FDA fast track designation for recAP in Acute Kidney Injury
  • Apr 19, 2016: AM-Pharma STOP-AKI Phase II trial nominated for "Most Innovative Clinical Trial Design"
  • Mar 14, 2016: Quark Pharmaceuticals Doses First Patient In Two Pivotal Clinical Studies of RNAi-Based Therapeutic QPI-1002
  • Feb 29, 2016: Thrasos Announces Promising Results for Phase II THR-184 Dose Ranging Clinical Study for the Prevention of Acute Kidney Injury (AKI)
  • Jan 06, 2016: DURECT Announces Positive Phase 1 Data for DUR-928
  • Dec 14, 2015: NephroGenex Announces FDA Clearance Of IND Application For Clinical Study Of Intravenous Pyridorin In The Treatment Of Acute Kidney Injury
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by A1M Pharma AB, H1 2017
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Alloksys Life Sciences BV, H1 2017
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Am-Pharma BV, H1 2017
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Angion Biomedica Corp, H1 2017
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Atox Bio Ltd, H1 2017
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Cellmid Ltd, H1 2017
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Complexa Inc, H1 2017
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by DiaMedica Therapeutics Inc, H1 2017
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by DURECT Corp, H1 2017
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Evotec AG, H1 2017
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Exponential Biotherapies Inc, H1 2017
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by G1 Therapeutics Inc, H1 2017
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Kringle Pharma Inc, H1 2017
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Mitotech SA, H1 2017
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by NephroGenex Inc, H1 2017
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by NeuroVive Pharmaceutical AB, H1 2017
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Nyken BV, H1 2017
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by ProMetic Life Sciences Inc, H1 2017
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Quark Pharmaceuticals Inc, H1 2017
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Rediscovery Life Sciences, H1 2017
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Regulus Therapeutics Inc, H1 2017
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by SBI Pharmaceuticals Co Ltd, H1 2017
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Spherium Biomed SL, H1 2017
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by STATegics Inc, H1 2017
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Stealth BioTherapeutics Inc, H1 2017
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Thrasos Therapeutics Inc, H1 2017
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Torrent Pharmaceuticals Ltd, H1 2017
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Xigen SA, H1 2017
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects, H1 2017
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top